Ellen Lubman, MBA
Chief Business Officer, Werewolf Therapeutics
Ellen Lubman, MBA has served as Werewolf’s Chief Business Officer since August 2020. From October 2018 to July 2020, Ms. Lubman served as the Chief Business Officer at Impel NeuroPharma, Inc., a publicly traded biotechnology company focused on neurological diseases. Prior to Impel, she was the Vice President of External Science & Innovation at Forest Labs, from February 2014 until its acquisition by Actavis plc in July 2014, and served in the same role at Actavis through June 2018 during which time Actavis merged with and renamed itself Allergan plc. Prior to Allergan, Ms. Lubman held numerous executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank and Abbott Labs. Ms. Lubman has served on the board of directors of Reunion Neuroscience, Inc., a publicly traded biotechnology company, since June 2021. Ms. Lubman serves on the Advisory Board of TMRW.org. Ms. Lubman also currently serves on the Scientific Advisory Board of the Daedalus Innovation Fund of Weill-Cornell, the board of directors of Gilda’s Club of NYC, and is the Southern California Chairwoman of Executive Women in BIO. Ms. Lubman earned her MBA from Stanford Graduate School of Business with a focus on Global Management and her BA in Biology from Rutgers College.